Simpler HIV pill tested for older adults

NCT ID NCT05911360

Summary

This study is testing if switching to a simpler, two-drug HIV pill works as well as a three-drug pill for keeping the virus suppressed. It involves 205 people living with HIV who are 50 or older and have had their virus under control for at least a year. The main goal is to see if the simpler regimen is just as effective and safe after 48 weeks.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • GSK Investigational Site

    Phoenix, Arizona, 85015, United States

  • GSK Investigational Site

    Bakersfield, California, 93301, United States

  • GSK Investigational Site

    Palm Springs, California, 92262, United States

  • GSK Investigational Site

    Washington D.C., District of Columbia, 20005, United States

  • GSK Investigational Site

    Ft. Pierce, Florida, 34982, United States

  • GSK Investigational Site

    Miami, Florida, 33133, United States

  • GSK Investigational Site

    West Palm Beach, Florida, 33407, United States

  • GSK Investigational Site

    Augusta, Georgia, 30912, United States

  • GSK Investigational Site

    Decatur, Georgia, 30033, United States

  • GSK Investigational Site

    Macon, Georgia, 31201, United States

  • GSK Investigational Site

    Boston, Massachusetts, 02043, United States

  • GSK Investigational Site

    Berkley, Michigan, 48072, United States

  • GSK Investigational Site

    Detroit, Michigan, 48202, United States

  • GSK Investigational Site

    Kansas City, Missouri, 64111, United States

  • GSK Investigational Site

    Omaha, Nebraska, 68198, United States

  • GSK Investigational Site

    Las Vegas, Nevada, 89106, United States

  • GSK Investigational Site

    The Bronx, New York, 10467, United States

  • GSK Investigational Site

    Charlotte, North Carolina, 28204, United States

  • GSK Investigational Site

    Greensboro, North Carolina, 27401, United States

  • GSK Investigational Site

    Wilmington, North Carolina, 28401-7684, United States

  • GSK Investigational Site

    Akron, Ohio, 44304, United States

  • GSK Investigational Site

    Portland, Oregon, 97239, United States

  • GSK Investigational Site

    Philadelphia, Pennsylvania, 19104, United States

  • GSK Investigational Site

    Austin, Texas, 78705, United States

  • GSK Investigational Site

    Innsbruck, 6020, Austria

  • GSK Investigational Site

    Vienna, 1100, Austria

  • GSK Investigational Site

    Brussels, 1200, Belgium

  • GSK Investigational Site

    Ghent, 9000, Belgium

  • GSK Investigational Site

    Toronto, Ontario, M5G 2N2, Canada

  • GSK Investigational Site

    Montreal, Quebec, H2L 1N9, Canada

  • GSK Investigational Site

    Montreal, Quebec, H4A 3J1, Canada

  • GSK Investigational Site

    Nice, 6202, France

  • GSK Investigational Site

    Orléans, 45100, France

  • GSK Investigational Site

    Paris, 75004, France

  • GSK Investigational Site

    Freiburg im Breisgau, 79106, Germany

  • GSK Investigational Site

    Hanover, 30625, Germany

  • GSK Investigational Site

    München, 80336, Germany

  • GSK Investigational Site

    Milan, 20142, Italy

  • GSK Investigational Site

    Modena, 41100, Italy

  • GSK Investigational Site

    Roma, 161, Italy

  • GSK Investigational Site

    Torino, 10149, Italy

  • GSK Investigational Site

    Mérida, 97070, Mexico

  • GSK Investigational Site

    Monterrey, 64460, Mexico

  • GSK Investigational Site

    Amsterdam, 1105 AZ, Netherlands

  • GSK Investigational Site

    Rotterdam, 3079 DZ, Netherlands

  • GSK Investigational Site

    Utrecht, 3584 CX, Netherlands

  • GSK Investigational Site

    Porto, 4099-001, Portugal

  • GSK Investigational Site

    Porto, 4200-319, Portugal

  • GSK Investigational Site

    Vila Nova de Gaia, 4434-502, Portugal

  • GSK Investigational Site

    Guadalajara, 19002, Spain

  • GSK Investigational Site

    Manresa Barcelona, 08243, Spain

  • GSK Investigational Site

    Sabadell Barcelona, 8208, Spain

  • GSK Investigational Site

    Zaragoza, 50009, Spain

  • GSK Investigational Site

    Liverpool, L7 8XP, United Kingdom

  • GSK Investigational Site

    London, SE1 9RT, United Kingdom

  • GSK Investigational Site

    London, SW7 2AZ, United Kingdom

Conditions

Explore the condition pages connected to this study.